Patents by Inventor Chen W Liaw

Chen W Liaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-endogenous, constitutively activated human protein-coupled receptors
    Patent number: 6555339
    Abstract: Disclosed are constitutively activated, non-endogenous versions of endogenous human GPCRs comprising the following amino acid sequence region (C-terminus to N-terminus orientation) and/or the following nucleic acid sequence region (3′ to 5′ orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR: P1AA15X  (a) and/or Pcodon(AA-codon)15Xcodon,  (b) respectively. In a preferred embodiment, P1 and Pcodon are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively, located within TM6 of the non-endogenous GPCR; AA15 and (AA-codon)15 are 15 endogenous amino acid residues and 15 codons encoding endogenous amino acid residues, respectively; and X and Xcodon are non-endogenous lysine and non-endogenous nucleic acid region encoding lysine, respectively, located within IC3 of the non-endogenous GPCR.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: April 29, 2003
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Chen W. Liaw, Dominic P. Behan, Derek T. Chalmers
  • Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
    Patent number: 6541209
    Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: April 1, 2003
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Dominic P. Behan, Derek T. Chalmers, Chen W. Liaw, Joseph F. Russo, William J. Thomsen
  • Endogenous and non-endogenous versions of human G protein-coupled receptors
    Publication number: 20030023069
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: February 26, 2002
    Publication date: January 30, 2003
    Inventors: Chen W. Liaw, Derek T. Chalmers, Dominic P. Behan, Dominique Maciejewski-Lenior, James N. Leonard, I-Lin Lin, Daniel Ortuno
  • Human orphan G protein-coupled receptors
    Publication number: 20030017528
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: June 6, 2001
    Publication date: January 23, 2003
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Non-endogenous, constitutively activated human G protein-coupled receptors
    Publication number: 20030018182
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 7, 2001
    Publication date: January 23, 2003
    Inventors: Dominic P. Behan, Karin Lehmann-Bruinsma, Derek T. Chalmers, Ruoping Chen, Huong T. Dang, Martin Gore, Chen W. Liaw, I-Lin Lin, Kevin Lowitz, Carol White
  • Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
    Patent number: 6420541
    Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: July 16, 2002
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Dominic P. Behan, Derek T. Chalmers, Chen W. Liaw, Joseph F. Russo, William J. Thomsen
  • Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
    Patent number: 6150393
    Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT.sub.2A and human 5-HT.sub.2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT.sub.2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT.sub.2A receptors.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: November 21, 2000
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Dominic P. Behan, Derek T. Chalmers, Nigel R. A. Beeley, Richard J. Foster, Robert C. Glen, Michael S. Lawless, Chen W. Liaw, Qian Liu, Frederique Menzaghi, Joseph F. Russo, Julian R. Smith, William J. Thomsen
  • Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
    Patent number: 6140509
    Abstract: A compound of formula (C) useful as a serotonin receptor modulator
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: October 31, 2000
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Dominic P. Behan, Derek T. Chalmers, Richard J. Foster, Robert C. Glen, Michael S. Lawless, Chen W. Liaw, Qian Liu, Joseph F. Russo, Julian R. Smith, William J. Thomsen
  • 5-HT2A receptor inverse agonists
    Patent number: 6107324
    Abstract: Disclosed herein is a new class of pyrazole compounds which act at the 5HT.sub.2A receptors.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: August 22, 2000
    Assignees: Arena Pharmaceuticals Inc., Tripos, Inc.
    Inventors: Dominic P. Behan, Derek T. Chalmers, Richard J. Foster, Robert C. Glen, Michael S. Lawless, Chen W. Liaw, Qian Liu, Joseph F. Russo, Julian R. Smith, William J. Thomsen